A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 07 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OSE 2101 (Primary) ; Docetaxel; Pemetrexed
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms ATALANTE-1
Sponsors OSE Immunotherapeutics; OSE Pharma

Most Recent Events

31 Jan 2024 Status changed from active, no longer recruiting to discontinued (due to COVID-19).
11 Sep 2023 According to a OSE Immunotherapeutics media release, data from this study were presented at the peer-reviewed publication in Annals of Oncology.
11 Sep 2023 Results presented in the OSE Immunotherapeutics media release .

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight